TOWARDS THE LOWEST EFFICACIOUS DOSE (TOLEDO): RESULTS OF A MULTICENTER NON-INFERIORITY RANDOMIZED OPEN-LABEL CONTROLLED TRIAL ASSESSING TOCILIZUMAB OR ABATACEPT INJECTION SPACING IN RHEUMATOID ARTHRITIS PATIENTS IN REMISSION

Category Primary study
JournalANNALS OF THE RHEUMATIC DISEASES
Year 2019
This article has no abstract
Epistemonikos ID: c8d122a252f7893ee7ae92177f0a79788bb0114a
First added on: Mar 23, 2022